Back to top
more

Zoetis (ZTS)

(Delayed Data from NYSE)

$150.88 USD

150.88
3,565,640

+1.32 (0.88%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $150.87 -0.01 (-0.01%) 7:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).

USNA or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

USNA vs. ZTS: Which Stock Is the Better Value Option?

Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.

Zoetis (ZTS) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zoetis (ZTS) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of 6.82% and 0.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 60% and 14.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in second-quarter 2023, partially offset by lower sales of swine products.

The Zacks Analyst Blog Highlights Johnson & Johnson, Zoetis, Lam Research, Aon and Dominion Energy

by Zacks Equity Research

Johnson & Johnson, Zoetis, Lam Research, Aon and Dominion Energy are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Johnson & Johnson, Zoetis & Lam Research

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Zoetis (ZTS) and Lam Research Corporation (LRCX).

Here's How Much a $1000 Investment in Zoetis Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last?

by Zacks Equity Research

Zoetis (ZTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

Wall Street Analysts Believe Zoetis (ZTS) Could Rally 27.94%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 27.9% in Zoetis (ZTS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zoetis (ZTS) Just Reclaimed the 20-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

If You Invested $1000 in Zoetis a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Should You Invest in the VanEck Agribusiness ETF (MOO)?

by Zacks Equity Research

Sector ETF report for MOO

Zoetis (ZTS) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Zoetis (ZTS) closed the most recent trading day at $170.74, moving -0.4% from the previous trading session.

Zoetis (ZTS) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Zoetis (ZTS) closed at $163.09 in the latest trading session, marking a -0.74% move from the prior day.

The Zacks Analyst Blog Highlights Microsoft, BP, Zoetis, Lululemon Athletica and Weyerhaeuser

by Zacks Equity Research

Microsoft, BP, Zoetis, Lululemon Athletica and Weyerhaeuser are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Microsoft, BP & Zoetis

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), BP p.l.c. (BP) and Zoetis Inc. (ZTS).

Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.

Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zoetis (ZTS) Q1 Earnings Top Estimates

by Zacks Equity Research

Zoetis (ZTS) delivered earnings and revenue surprises of 3.15% and 0.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More

by Kinjel Shah

Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.

Why Earnings Season Could Be Great for Zoetis (ZTS)

by Zacks Equity Research

Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Aquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 210% and 9.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?